| Stanford University, Ph.D | |
| Biochemistry | |
| University of California, BS | |
| Biochemistry |
Dr. Shoemaker is Fate’s chief technology officer and is leading the company’s drug discovery efforts.
Dr. Shoemaker was previously chief scientific officer of ICxBiosystems, which develops advanced detection technologies for use in biodefense, cancer and prenatal diagnostics. He led the technology team in establishing molecular tools to enrich and analyze rare cell populations.
From 2003 to 2005, he was chief scientific officer of GHC Technologies and led the research and development of rapid ultrasensitive detection assays for biodefense and clinical point-of-care diagnostics.
From 1998 to 2003, Dr. Shoemaker held several positions at Merck Research Laboratories, including director of Target Discovery, senior director at Rosetta Inpharmatics and research fellow in the Department of Molecular Neurosciences, where his main focus was on target identification and biomarker discovery.
Dr. Shoemaker’s research at Merck achieved publications in top journals, including Nature, Science and Nature Biotechnology.
Dr. Shoemaker received his Ph.D. in biochemistry from Stanford University and his B.S. in biochemistry from University of California, Santa Barbara.
